CeriBell (CBLL) said Tuesday its Clarity algorithm has received 510(k) clearance from the US Food and Drug Administration for the detection of electrographic seizures in patients aged at least one.
The company said that based on its assessment, the algorithm now provides coverage across the widest age range addressed by a seizure detection technology, allowing hospitals to detect electrographic seizures in pediatric and adult patients alike.
The algorithm is designed for use with the company's electroencephalography headbands that are currently marketed for adults and cleared for use in patients of all ages, the company said.
CeriBell said its artificial intelligence-powered point-of-care electroencephalography system enables prompt bedside neurological evaluation and provides real-time insights into patient condition.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.